Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib

Current Gastroenterology Reports

Volumn 10, Issue 6, 2008, Pages 555-561

  Cassier, Philippe A ^a   Dufresne, Armelle ^a   Arifi, Samia ^a   Sayadi, Hiba ^a   Ray Coquard, Isabelle ^a   Bringuier, Pierre Paul ^a   Scoazec, Jean Yves ^a   Alberti, Laurent ^a   Blay, Jean Yves ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFINITOR; ANTINEOPLASTIC AGENT; DASATINIB; EVEROLIMUS; HEAT SHOCK PROTEIN; IMATINIB; MIDOSTAURIN; MOTESANIB; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TANESPIMYCIN HYDROQUINONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; BLEEDING; CANCER GROWTH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; EDEMA; FATIGUE; GASTRITIS; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GASTROINTESTINAL TOXICITY; GENE MUTATION; HAND FOOT SYNDROME; HEMORRHAGIC GASTRITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; MOLECULAR GENETICS; MONOTHERAPY; MUTATIONAL ANALYSIS; MYALGIA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; STOMACH CARCINOGENESIS; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; PIPERAZINES; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION;

EID: 60749129979     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0102-z     Document Type: Review

References (67)

1. Nilsson B, Bumming P, Meis-Kindblom JM, et al.: Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005, 103: 821-829.
2. Monges G, Coindre J, Scoazec J, et al.: Incidence of gastrointestinal stromal tumors (GISTs) in France: Results of the PROGIST survey conducted among pathologists [abstract]. J Clin Oncol (Meeting Abstracts) 2007, 25: 10047.
3. Rubin BP, Heinrich MC, Corless CL: Gastrointestinal stromal tumour. Lancet 2007, 369: 1731-1741.
4. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347: 472-480.
5. Verweij J, Casali PG, Zalcberg J, et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004, 364: 1127-1134.
6. Blanke CD, Demetri GD, Von Mehren M, et al.: Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate [abstract]. J Clin Oncol (Meeting Abstracts) 2006, 24: 9528.
7. Heinrich MC, Maki RG, Corless CL, et al.: Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status [abstract]. J Clin Oncol (Meeting Abstracts) 2006, 24: 9502.
8. Demetri GD, van Oosterom AT, Garrett CR, et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006, 368: 1329-1338.
9. Stroobants S, Goeminne J, Seegers M, et al.: 18FDGpositron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003, 39: 2012-2020.
10. Antoch G, Kanja J, Bauer S, et al.: Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004, 45: 357-365.
11. Choi H, Charnsangavej C, Faria SC, et al.: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007, 25: 1753-1759.
12. Benjamin RS, Choi H, Macapinlac HA, et al.: We should desist using RECIST, at least in GIST. J Clin Oncol 2007, 25: 1760-1764.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92: 205-216.
14. De Giorgi U, Aliberti C, Benea G, et al.: Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2005, 11: 6171-6176.
15. Shankar S, Vansonnenberg E, Desai J, et al.: Gastrointestinal stromal tumor: New nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005, 235: 892-898.
16. Heinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21: 4342-4349.
17. Corless CL, Schroeder A, Griffith D, et al.: PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005, 23: 5357-5364.
18. Debiec-Rychter M, Cools J, Dumez H, et al.: Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinibresistant mutants. Gastroenterology 2005, 128: 270-279.
19. Heinrich MC, Corless CL, Blanke CD, et al.: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006, 24: 4764-4774.
20. Debiec-Rychter M, Dumez H, Judson I, et al.: Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004, 40: 689-695.
21. Van Glabbeke MM, Owzar K, Rankin C, et al.: Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A metaanalysis based on 1,640 patients (pts) [abstract]. J Clin Oncol (Meeting Abstracts) 2007, 25: 10004.
22. Antonescu CR, Besmer P, Guo T, et al.: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005, 11: 4182-4190.
23. Demetri GD, Wang Y, Wehrle E, et al.: Correlation of imatinib plasma levels with clinical benefit in patients (Pts) with unresectable/ metastatic gastrointestinal tumors (GIST) [abstract 3]. Presented at the 2008 Gastrointestinal Cancers Symposium. Orlando, FL; January 25-27, 2008.
24. Tamborini E, Bonadiman L, Greco A, et al.: A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004, 127: 294-299.
25. Wakai T, Kanda T, Hirota S, et al.: Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer 2004, 90: 2059-2061.
26. Chen LL, Trent JC, Wu EF, et al.: A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004, 64: 5913-5919.
27. Tamborini E, Gabanti E, Lagonigro MS, et al.: KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient [letter]. Cancer Res 2005, 65: 1115.
28. McLean SR, Gana-Weisz M, Hartzoulakis B, et al.: Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Mol Cancer Ther 2005, 4: 2008-2015.
29. Wardelmann E, Thomas N, Merkelbach-Bruse S, et al.: Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005, 6: 249-251.
30. Grimpen F, Yip D, McArthur G, et al.: Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. Lancet Oncol 2005, 6: 724-727.
31. Bertucci F, Goncalves A, Monges G, et al.: Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour. Oncol Rep 2006, 16: 97-101.
32. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al.: Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006, 12: 1743-1749.
33. Haller F, Detken S, Schulten HJ, et al.: Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 2007, 14: 526-532.
34. Al-Batran SE, Hartmann JT, Heidel F, et al.: Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: A three-center-based study of 38 patients. Gastric Cancer 2007, 10: 145-152.
35. Utsunomiya T, Okamoto M, Yano S, et al.: Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: Report of a case. Surg Today 2008, 38: 65-67.
36. Desai J, Shankar S, Heinrich MC, et al.: Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2007, 13: 5398-5405.
37. Grabellus F, Ebeling P, Worm K, et al.: Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour. Gut 2007, 56: 1025-1026.
38. Tabone S, Theou N, Wozniak A, et al.: KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs). Biochim Biophys Acta 2005, 1741: 165-172.
39. Tabone-Eglinger S, Subra F, El Sayadi H, et al.: KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. Clin Cancer Res 2008, 14: 2285-2294.
40. Theou N, Gil S, Devocelle A, et al.: Multidrug resistance proteins in gastrointestinal stromal tumors: Site-dependent expression and initial response to imatinib. Clin Cancer Res 2005, 11: 7593-7598.
41. Heinrich MC, Corless CL, Liegl B, et al.: Mechanisms of sunitinib malate (SU) resistance in gastrointestinal stromal tumors (GISTs) [abstract]. J Clin Oncol (Meeting Abstracts) 2007, 25: 10006.
42. Bonvalot S, Eldweny H, Pechoux CL, et al.: Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006, 13: 1596-1603.
43. Andtbacka RH, Ng CS, Scaife CL, et al.: Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007, 14: 14-24.
44. Raut CP, Posner M, Desai J, et al.: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006, 24: 2325-2331.
45. Gronchi A, Fiore M, Miselli F, et al.: Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/ metastatic GIST. Ann Surg 2007, 245: 341-346.
46. Weisberg E, Wright RD, Jiang J, et al.: Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006, 131: 1734-1742.
47. Von Mehren M, Reichardt P, Casali PG, et al.: A phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) - study update [abstract]. J Clin Oncol (Meeting Abstracts) 2007, 25: 10023.
48. Polverino A, Coxon A, Starnes C, et al.: AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006, 66: 8715-8721.
49. Rosen LS, Kurzrock R, Mulay M, et al.: Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007, 25: 2369-2376.
50. Benjamin RS, Choi H, Macapinlac HA, et al.: Response of gastrointestinal stromal tumors (GISTs) to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression [abstract]. J Clin Oncol (Meeting Abstracts) 2006, 24: 9506.
51. Yamada Y, Sawaki A, Nishida T, et al.: Phase II study of motesanib diphosphate (AMG 706) in Japanese patients (pts) with advanced gastrointestinal stromal tumors (GISTs) who developed progressive disease or relapsed while on imatinib mesylate [abstract 107]. Presented at the 2008 Gastrointestinal Cancers Symposium. Orlando, FL; January 25-27, 2008.
52. Wilhelm S, Carter C, Lynch M, et al.: Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5: 835-844.
53. Guo T, Agaram NP, Wong GC, et al.: Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007, 13: 4874-4881.
54. Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356: 125-134.
55. Wiebe L, Kasza KE, Maki RG, et al.: Activity of sorafenib (SOR) in patients with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium [abstract]. J Clin Oncol (Meeting Abstracts) 2008, 26: 10502.
56. Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P: Dasatinib. Nat Rev Drug Discov 2006, 5: 717-718.
57. Schittenhelm MM, Shiraga S, Schroeder A, et al.: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006, 66: 473-481.
58. Propper DJ, McDonald AC, Man A, et al.: Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001, 19: 1485-1492.
59. Stone RM, DeAngelo DJ, Klimek V, et al.: Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005, 105: 54-60.
60. Monnerat C, Henriksson R, Le Chevalier T, et al.: Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 2004, 15: 316-323.
61. Eder JP Jr, Garcia-Carbonero R, Clark JW, et al.: A phase I trial of daily oral 4-N-benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Invest New Drugs 2004, 22: 139-150.
62. Bauer S, Duensing A, Demetri GD, Fletcher JA: KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 2007, 26: 7560-7568.
63. Duensing A, Medeiros F, McConarty B, et al.: Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004, 23: 3999-4006.
64. van Oosterom AT, Dumez H, Desai J, et al.: Combination signal transduction inhibition: A phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM [abstract]. J Clin Oncol (Meeting Abstracts) 2004, 22: 3002.
65. van Oosterom A, Reichardt P, Blay JY, et al.: A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update [abstract]. J Clin Oncol (Meeting Abstracts) 2005, 23: 9033.
66. Whitesell L, Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5: 761-772.
67. Wagner AJ, Morgan JA, Chugh R, et al.: Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from a phase I trial. J Clin Oncol (Meeting Abstracts) 2008, 26: 10503.